101 related articles for article (PubMed ID: 7581715)
1. Radiolabeling of antibodies for therapy and diagnosis.
Baranowska-Kortylewicz J; Dalrymple GV; Quadri SM; Harrison KA
Methods Mol Biol; 1995; 51():423-39. PubMed ID: 7581715
[No Abstract] [Full Text] [Related]
2. Methods of measuring thyroglobulin and peptide-methylcoumarinamide hydrolysis by autoantibodies.
Li L; Kalaga R; Kaveri S; Paul S
Methods Mol Biol; 1995; 51():417-21. PubMed ID: 7581714
[No Abstract] [Full Text] [Related]
3. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA
J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
[TBL] [Abstract][Full Text] [Related]
4. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.
Govindan SV; Shih LB; Goldenberg DM; Sharkey RM; Karacay H; Donnelly JE; Losman MJ; Hansen HJ; Griffiths GL
Bioconjug Chem; 1998; 9(6):773-82. PubMed ID: 9815172
[TBL] [Abstract][Full Text] [Related]
5. Centralized radiolabeling of antibodies for radioimmunotherapy.
Colcher D
J Nucl Med; 1998 Aug; 39(8 Suppl):11S-13S. PubMed ID: 9708565
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic modeling and absorbed dose estimation for chimeric anti-CEA antibody in humans.
Odom-Maryon TL; Williams LE; Chai A; Lopatin G; Liu A; Wong YC; Chou J; Clarke KG; Raubitschek AA
J Nucl Med; 1997 Dec; 38(12):1959-66. PubMed ID: 9430477
[TBL] [Abstract][Full Text] [Related]
7. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system.
Goodwin DA; Meares CF; Osen M
J Nucl Med; 1998 Oct; 39(10):1813-8. PubMed ID: 9776294
[TBL] [Abstract][Full Text] [Related]
8. Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates.
Gansow OA
Int J Rad Appl Instrum B; 1991; 18(4):369-81. PubMed ID: 1864725
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunotherapy of solid tumors: the promise of pretargeting strategies using bispecific antibodies and radiolabeled haptens.
Reilly RM
J Nucl Med; 2006 Feb; 47(2):196-9. PubMed ID: 16455623
[No Abstract] [Full Text] [Related]
10. Principles of radioimmunotherapy for hematologists and oncologists.
Press OW; Rasey J
Semin Oncol; 2000 Dec; 27(6 Suppl 12):62-73. PubMed ID: 11226002
[TBL] [Abstract][Full Text] [Related]
11. Radiopharmaceutical management of 90Y/111In labeled antibodies: shielding and quantification during preparation and administration.
van Hemert FJ; Sloof GW; Schimmel KJ; Vervenne WL; van Eck-Smrr BL; Busemann-Sokole E
Ann Nucl Med; 2006 Oct; 20(8):575-81. PubMed ID: 17134028
[TBL] [Abstract][Full Text] [Related]
12. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.
Goldenberg DM; Sharkey RM; Paganelli G; Barbet J; Chatal JF
J Clin Oncol; 2006 Feb; 24(5):823-34. PubMed ID: 16380412
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of indium-111- and yttrium-90-labeled linker-immunoconjugates in nude mice and dogs.
Quadri SM; Vriesendorp HM; Leichner PK; Williams JR
J Nucl Med; 1993 Jun; 34(6):938-45. PubMed ID: 8509861
[TBL] [Abstract][Full Text] [Related]
14. International Clinical Trials in Radiation Oncology. Isotopic immunotherapy: radiolabelled antibody.
Order SE
Int J Radiat Oncol Biol Phys; 1988; 14 Suppl 1():S77-81. PubMed ID: 3292485
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of radiolabeled polyclonal antiferritin in patients with Hodgkin's disease.
Lai J; Quadri SM; Borchardt PE; Harris L; Wucher R; Askew E; Schweichel L; Vriesendorp HM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3315s-3323s. PubMed ID: 10541380
[TBL] [Abstract][Full Text] [Related]
16. Quality control of radiolabeled monoclonal antibodies.
Khazaeli MB
Cancer Biother Radiopharm; 2000 Dec; 15(6):529-30. PubMed ID: 11190485
[No Abstract] [Full Text] [Related]
17. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
18. Pretargeted radioimmunotherapy.
Meredith RF; Buchsbaum DJ
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S57-9. PubMed ID: 16979441
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy of refractory or relapsed Hodgkin's lymphoma with 90Y-labelled antiferritin antibody.
Decaudin D; Levy R; Lokiec F; Morschhauser F; Djeridane M; Kadouche J; Pecking A
Anticancer Drugs; 2007 Jul; 18(6):725-31. PubMed ID: 17762404
[TBL] [Abstract][Full Text] [Related]
20. A new method for site-specific labelling of the oligosaccharide chain of antibodies: preliminary results.
Wunderlich G; Schwarz U; Franke WG; Brossmer R
J Nucl Biol Med (1991); 1994 Dec; 38(4 Suppl 1):15-7. PubMed ID: 7632760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
